<scp>H</scp>artmann <scp>S</scp>tahelin (1925–2011) and the contested history of cyclosporin <scp>A</scp>

Cheng, Myra

doi:10.1111/ctr.12072

Cited by 5 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 1969, Dr. E. Donnall Thomas conducted the first bone marrow transplantation in the US, although the success of the allogeneic treatment remained exclusive. In 1972, the year marked the discovery of cyclosporine (the immune suppressive drug), 14 the first successes of allogeneic transplantation for aplastic anemia and acute myeloid leukemia were reported in a 16-year-old girl. 15 From the 1960s to the 1970s, series of works conducted by Friendenstein and coworkers on bone marrow aspirates demonstrated the relationship between osteogenic differentiation and a minor subpopulation of cells derived from bone marrow.…”

Section: Introductionmentioning

confidence: 99%

Stem cell-based therapy for human diseases

Hoang

Pham

Bach

et al. 2022

Sig Transduct Target Ther

478

138

View full text Add to dashboard Cite

Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent stem cells (hPSCs) and multipotent mesenchymal stem cells (MSCs), has recently emerged as a key player in regenerative medicine. hPSCs are defined as self-renewable cell types conferring the ability to differentiate into various cellular phenotypes of the human body, including three germ layers. MSCs are multipotent progenitor cells possessing self-renewal ability (limited in vitro) and differentiation potential into mesenchymal lineages, according to the International Society for Cell and Gene Therapy (ISCT). This review provides an update on recent clinical applications using either hPSCs or MSCs derived from bone marrow (BM), adipose tissue (AT), or the umbilical cord (UC) for the treatment of human diseases, including neurological disorders, pulmonary dysfunctions, metabolic/endocrine-related diseases, reproductive disorders, skin burns, and cardiovascular conditions. Moreover, we discuss our own clinical trial experiences on targeted therapies using MSCs in a clinical setting, and we propose and discuss the MSC tissue origin concept and how MSC origin may contribute to the role of MSCs in downstream applications, with the ultimate objective of facilitating translational research in regenerative medicine into clinical applications. The mechanisms discussed here support the proposed hypothesis that BM-MSCs are potentially good candidates for brain and spinal cord injury treatment, AT-MSCs are potentially good candidates for reproductive disorder treatment and skin regeneration, and UC-MSCs are potentially good candidates for pulmonary disease and acute respiratory distress syndrome treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Stem cell-based therapy for human diseases

Hoang

Pham

Bach

et al. 2022

Sig Transduct Target Ther

478

138

View full text Add to dashboard Cite

show abstract

“…In the 1930s, Leo Sternbach from the University in Cracow synthesized several heptoxdiazines in order to develop synthetic dyes. Cyclosporin was testing as an anti-tubercular antibiotic but became the first immunosuppressive drug that changed the science and practice of organ transplantation [ 15 ]. Additionally, the latest story is about sildenafil (Viagra), which was developing as an antihypertensive drug but is becoming one of the best-selling drugs ever, leading to an entirely new pharmacological group in modern pharmacology.…”

Section: Drug Discoverymentioning

confidence: 99%

Drug Design—Past, Present, Future

Doytchinova

2022

Molecules

View full text Add to dashboard Cite

Drug design is a complex pharmaceutical science with a long history. Many achievements have been made in the field of drug design since the end of 19th century, when Emil Fisher suggested that the drug–receptor interaction resembles the key and lock interplay. Gradually, drug design has been transformed into a coherent and well-organized science with a solid theoretical background and practical applications. Now, drug design is the most advanced approach for drug discovery. It utilizes the innovations in science and technology and includes them in its wide-ranging arsenal of methods and tools in order to achieve the main goal: discovery of effective, specific, non-toxic, safe and well-tolerated drugs. Drug design is one of the most intensively developing modern sciences and its progress is accelerated by the implication of artificial intelligence. The present review aims to capture some of the most important milestones in the development of drug design, to outline some of the most used current methods and to sketch the future perspective according to the author’s point of view. Without pretending to cover fully the wide range of drug design topics, the review introduces the reader to the content of Molecules’ Special Issue “Drug Design—Science and Practice”.

show abstract

A Comprehensive Review of Calcineurin Inhibitors Used for Immunosuppression in Cardiac Transplantation

Engwenyu

Anderson

2021

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

Hartmann Stahelin (1925–2011) and the contested history of cyclosporin A

Cited by 5 publications

References 12 publications

Stem cell-based therapy for human diseases

Stem cell-based therapy for human diseases

Drug Design—Past, Present, Future

A Comprehensive Review of Calcineurin Inhibitors Used for Immunosuppression in Cardiac Transplantation

Contact Info

Product

Resources

About